Alzheimer's & Cognition
Latest News
Most with early AD not eligible for new antiamyloid drugs
Older patients aren’t eligible largely because of the presence of medical conditions or neuroimaging findings.
From the Journals
Few meet eligibility for newer Alzheimer’s drugs
Fewer than 10% of early Alzheimer’s patients in a real-world cohort would qualify for trials of anti–amyloid-beta monoclonal antibodies, a study...
News
Which factors distinguish superagers from the rest of us?
The superagers indicated that generally they had been more active than the control subjects during their middle years.
From the Journals
‘Emerging’ biomarker may predict mild cognitive impairment years before symptoms
Low NPTX2 levels are predictive of MCI symptom onset more than 7 years in advance.
News
Inhaling pleasant scents during sleep tied to a dramatic boost in cognition
“To my knowledge, that level of [memory] improvement is far greater than anything that has been reported for healthy older adults ...”
Latest News
Depression at any stage of life tied to increased dementia risk
The double risk persists regardless of when in life depression is diagnosed.
Latest News
Medicare to pay for at-home dementia care coordination
The program is voluntary and will be open to Medicare-enrolled clinicians and other providers who can assemble an interdisciplinary care team and...
Latest News
Tooth loss, gum disease tied to hippocampal atrophy
For those with severe gum disease, each additional lost tooth was associated with a faster rate of brain shrinkage, equivalent to 1.3 years of...
Latest News
New Alzheimer’s drugs: Setting realistic expectations
Most patients living with Alzheimer’s disease will not qualify for treatment with these drugs, and those who do may suffer serious side effects....
From the Journals
No cognitive benefit from meditation, learning a language?
The findings contradict the researchers’ earlier work that found mindfulness meditation boosted cognitive function in older adults with subjective...
Conference Coverage
Oral tau inhibitor continues to show promise in Alzheimer’s
“This is the first tau aggregation inhibitor to reach the phase 3 stage of development and to produce results like this.”